Compare CNNE & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNNE | ASMB |
|---|---|---|
| Founded | 2014 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 497.5M | 440.0M |
| IPO Year | 2017 | 2010 |
| Metric | CNNE | ASMB |
|---|---|---|
| Price | $12.86 | $30.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $21.33 | ★ $44.20 |
| AVG Volume (30 Days) | ★ 678.8K | 70.0K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.73% | N/A |
| EPS Growth | N/A | ★ 91.78 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $499,700,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $235.63 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3.37 | N/A |
| 52 Week Low | $10.46 | $9.68 |
| 52 Week High | $21.96 | $39.71 |
| Indicator | CNNE | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 63.53 | 56.00 |
| Support Level | $11.54 | $29.31 |
| Resistance Level | $16.41 | $30.54 |
| Average True Range (ATR) | 0.46 | 1.44 |
| MACD | 0.24 | 0.14 |
| Stochastic Oscillator | 97.40 | 82.49 |
Cannae Holdings Inc is an investment holding company that acquires and actively manages equity interests in operating businesses across various industries. The Company focuses on long-term ownership and seeks to create value by supporting the growth and operations of its portfolio companies through management expertise and strategic oversight. The Company operates through four reportable segments: Restaurant Group, which includes the operations of O'Charleys and 99 Restaurants; Alight, which represents its ownership interest in a technology-enabled human capital and employee benefits solutions provider; Black Knight Football Club (BKFC), which holds interests in professional football clubs; and JANA, which represents its investment in an investment management firm.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.